NEWS
Announcement regarding theNew Exective Leadership Structure.
Toregem BioPharma Co., Ltd. Announced new executive leadership structure designed to support future business expansion and further enhance corporate value.As the Company enters the commercialization and expansion phase,Toregem would adopt a leadership structure that clearly delineates functional expertise and responsibilities, enabling rapid and consistent decision-making. Press release
Announcement for Completion of the PMDA Investigation of CTN (Clinical Trial Notification)for TRG035 Phase IIa Trial.
Toregem BioPharma Co., Ltd has submitted CTN to PMDA (Pharmaceuticals and Medical Devices Agency) regarding an exploratory clinical trial of an antibody drug (TRG035) for congenital tooth agenesis, and we are pleased to announce that the PMDA has completed the required investigation today 17-Aug-26. Press release
Selected for the "KYOTO overseas expansion challenging support subsidy program" & "Overseas Expansion Support Project for Startup in Kyoto (individual overseas Business Matching)"
With this support, we will create overseas joint research projects in dental regenerative medicine, form international partnerships for licensing agreements, get support with attending overseas events, promoting strategies and branding, while also making a concrete action plan to expand overseas and turn it into real results.
Toregem attend to the NFED（National Foundation for Ectodermal Dysplasias）Family Conference in St.Luois.
Our President and CEO, Dr. Honoka Kiso, is attending the annual Family Conference held by NFED (National Foundation for Ectodermal Dysplasias). At this event, patients with congenital ectodermal dysplasias and their families, as well as medical professionals and researchers, gather for information exchange and networking. We will deepen our understanding of the disease through interactions […]
Toregem Raises Approximately USD 5.3 Million (JPY 850 Million) in Pre-Series C Financing;Total Past Funding Exceeds USD 29 Million (JPY 4.6 Billion）With this fundinig, we will accelerate the clinical development of the world's first tooth regeneration treatment.
Toregem raised approximately USD 5.3 Million (JPY 850 million) in Pre-Series C financing round fundingThrough this funding, Toregem’s cumulative equity financing has reached approximately JPY 2.6 billion, and its cumulative funding, including grants and subsidies, has exceeded USD 29 Million (JPY 4.6 billion).With this funding, Toregem will conduct Phase II clinical trials of TRG035, a […]